Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pharvaris N.V.PHVS · Entity 4374 | Director | September 17, 2026 | September 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pharvaris N.V.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,500 |
Ending reported balance
After 2026-09-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-17 · Exercise / conversion · Acquired 14,493 · Balance 24,993 F1: This is a scheduled exercise and sale from 10b5-1 trading plan. Row 2 · 2026-09-17 · Sale · Disposed 14,493 · Balance 10,500 F1: This is a scheduled exercise and sale from 10b5-1 trading plan. F2: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.26 to $38.89. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.14 · Expires 2032-04-01 | Direct | 0 |
Reported balance
After 2026-09-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-17 · Exercise / conversion · Disposed 14,493 · Balance 0 F3: 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This is a scheduled exercise and sale from 10b5-1 trading plan.
F2: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.26 to $38.89. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3: 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 21, 2026 19:16 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,493 | $0.00 Strike: $18.14 | $0.00 |
DisclosureSEC source: 0001193125-26-396579 · ownership.xml · derivative · entry 3 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,493 shares Expires 2032-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 19:16 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 14,493 | $38.56 | $558,812.40 |
DisclosureSEC source: 0001193125-26-396579 · ownership.xml · nonDerivative · entry 2 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.26 to $38.89. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 19:16 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 14,493 | $18.14 | $262,903.02 |
DisclosureSEC source: 0001193125-26-396579 · ownership.xml · nonDerivative · entry 1 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 13:18 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,667 | $0.00 Strike: $22.31 | $0.00 |
DisclosureSEC source: 0001193125-26-393860 · ownership.xml · derivative · entry 3 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,667 shares Expires 2034-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the option vest on the 12-month anniversary. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 13:18 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 8,667 | $38.27 | $331,716.42 |
DisclosureSEC source: 0001193125-26-393860 · ownership.xml · nonDerivative · entry 2 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,500 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.175 to $38.43. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 13:18 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 8,667 | $22.31 | $193,360.77 |
DisclosureSEC source: 0001193125-26-393860 · ownership.xml · nonDerivative · entry 1 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 16:25 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001193125-26-388909 · ownership.xml · derivative · entry 3 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2031-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 16:25 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 8,000 | $37.55 | $300,396.00 |
DisclosureSEC source: 0001193125-26-388909 · ownership.xml · nonDerivative · entry 2 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,500 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $37.21 to $37.83. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 16:25 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 8,000 | $20.00 | $160,000.00 |
DisclosureSEC source: 0001193125-26-388909 · ownership.xml · nonDerivative · entry 1 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| May 15, 2026 Filed May 19, 2026 22:48 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,333 | $0.00 Strike: $22.31 | $0.00 |
DisclosureSEC source: 0001193125-26-231291 · ownership.xml · derivative · entry 4 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,667 Underlying: Common Stock · 5,333 shares Expires 2034-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the option vested on anniversary of grant, April 11th, 2025. Read SEC document |
| May 15, 2026 Filed May 19, 2026 22:48 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 4,667 | $29.82 | $139,154.54 |
DisclosureSEC source: 0001193125-26-231291 · ownership.xml · nonDerivative · entry 3 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 F2 · price: The reported price represents a weighted sale price for shares sold in multiple transactions on the reported date. The shares reported herein include shares of common stock acquired upon vestring of restricted stock units on various dates. The sales prices for the transactions ranged from $29.7750 to $29.74. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2026 Filed May 19, 2026 22:48 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 5,333 | $29.83 | $159,090.86 |
DisclosureSEC source: 0001193125-26-231291 · ownership.xml · nonDerivative · entry 2 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,167 F1 · price: The reported price represents a weighted sale price for shares sold in multiple transactions on the reported date. The shares reported herein include shares of common stock acquired upon vestring of restricted stock units on various dates. The sales prices for the transactions ranged from $29.6550 to $29.92. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2026 Filed May 19, 2026 22:48 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 5,333 | $22.31 | $118,979.23 |
DisclosureSEC source: 0001193125-26-231291 · ownership.xml · nonDerivative · entry 1 Glassman Robert · CIK 0001897890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.